Name: | Description: | Size: | Format: | |
---|---|---|---|---|
61.81 KB | Adobe PDF |
Advisor(s)
Abstract(s)
Background: Children with spina bifida represent the major risk group for latex sensitization.
Purpose: To determine the prevalence of latex
sensitization in these children and to identify risk factors.
Material and methods: We studied 57 patients
with spina bifida. The mean age was 5.6 years and the male/female ratio was 0.8/1. In all patients a questionnaire, skin prick test (SPT) with latex (UCBStallergènes,
Lofarma and ALK-Abelló), common aeroallergens and fruits (UCB-Stallergènes) and serum determination of total IgE (AlaSTAT) were performed.
Results: The prevalence of latex sensitization was 30 %; only two sensitized children (12 %) had symptoms after exposure. Risk factors for latex sensitization were age 5 years (p = 0.008; OR = 6.0;
95% CI = 1.7-22.1), having at least four previous surgical interventions (p < 0.0001; OR = 18.5; 95% CI = 3.6-94.8), having undergone surgery in the first
3 months of life (p = 0.008; OR = 5.4; 95%
CI = 0.7-29.2) and total serum IgE 44 IU/ml
(p = 0.03; OR = 3.8; 95 %CI = 1.1-13.1). Multiple logistic regression analysis showed that only a history of four or more surgical interventions (p < 0.0001; OR = 26.3; 95 %CI = 2.9-234.2) and total serum IgE 44 IU/ml (p = 0.02; OR = 8.6; 95% CI = 1.4-53.4)
were independently associated with latex
sensitization. Sex, family and personal allergic history, hydrocephalus with ventriculoperitoneal shunt,
cystourethrograms, intermittent bladder catheterization and atopy were not related to latex sensitization.
Conclusions: In children with spina bifida,
significant and independent risk factors identified for latex sensitization were multiple interventions and higher levels of total serum IgE. A prospective study
will clarify the clinical evolution of assymptomatic children sensitized to latex.
Description
Keywords
Látex Espinha Bífida Hipersensibilidade Criança Factores de Risco HDE ALER HDE NEU PED
Citation
Allergol et Immunopathol 2002;30(1):5-13.